{"schema_version":"secwatch.filing_event.v1","accession":"0001549595-23-000030","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2023-04-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.347019+00:00","generated_at":"2026-06-17T02:38:05.587337+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nurix licenses IRAK4 degrader to Gilead for $20M; Q1 net loss $40.7M","bullets":["Gilead exercised option to license NX-0479/GS-6791, triggering $20M payment; up to $425M in milestones plus tiered royalties up to low double-digits.","Q1 collaboration revenue $12.7M (up from $9.6M); net loss $40.7M ($0.75/share) vs $42.5M ($0.95) YoY.","Cash and marketable securities $325.6M as of Feb 28, 2023, down from $373.0M at Nov 30, 2022.","Achieved $7.5M in research milestones from Gilead ($6.5M) and Sanofi ($1.0M) during the quarter.","Anticipates presenting Phase 1 clinical data for NX-2127, NX-5948, and NX-1607 in H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001549595-23-000030","json":"https://secwatch.observer/filing/0001549595-23-000030.json","markdown":"https://secwatch.observer/filing/0001549595-23-000030.md","text":"https://secwatch.observer/filing/0001549595-23-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000154959523000030/0001549595-23-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000154959523000030/nrix-20230413.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T02:38:05.587337+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1c5e76600f90db60e1cb5676cc98f9975ad59bb3","claim":"Nurix Therapeutics, Inc. reported financial results for first quarter ended February 28, 2023.","evidence_excerpt":"On April 13, 2023, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal quarter ended February 28, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959523000030/0001549595-23-000030-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended February 28, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}